331 related articles for article (PubMed ID: 24669841)
1. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series.
Delsing CE; Gresnigt MS; Leentjens J; Preijers F; Frager FA; Kox M; Monneret G; Venet F; Bleeker-Rovers CP; van de Veerdonk FL; Pickkers P; Pachot A; Kullberg BJ; Netea MG
BMC Infect Dis; 2014 Mar; 14():166. PubMed ID: 24669841
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive interferon-γ immunotherapy in a pediatric case of Aspergillus terreus infection.
Assendorp EL; Gresnigt MS; Sprenkeler EGG; Meis JF; Dors N; van der Linden JWM; Henriet SSV
Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1915-1922. PubMed ID: 30027379
[TBL] [Abstract][Full Text] [Related]
3. Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?
Tapısız A
Expert Rev Anti Infect Ther; 2011 Mar; 9(3):339-46. PubMed ID: 21417873
[TBL] [Abstract][Full Text] [Related]
4. Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections.
Holt SL; Drew RH
Am J Health Syst Pharm; 2011 Jul; 68(13):1207-20. PubMed ID: 21690427
[TBL] [Abstract][Full Text] [Related]
5. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.
Kett DH; Shorr AF; Reboli AC; Reisman AL; Biswas P; Schlamm HT
Crit Care; 2011; 15(5):R253. PubMed ID: 22026929
[TBL] [Abstract][Full Text] [Related]
6. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
[TBL] [Abstract][Full Text] [Related]
7. [Echinocandins in children].
Leverger G; Le Guyader N
Arch Pediatr; 2011 May; 18 Suppl 1():S33-41. PubMed ID: 21596285
[TBL] [Abstract][Full Text] [Related]
8. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
9. Caspofungin therapy in immunocompromised children and neonates.
Somer A; Törün SH; Salman N
Expert Rev Anti Infect Ther; 2011 Mar; 9(3):347-55. PubMed ID: 21417874
[TBL] [Abstract][Full Text] [Related]
10. Echinocandins: The Expanding Antifungal Armamentarium.
Aguilar-Zapata D; Petraitiene R; Petraitis V
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S604-11. PubMed ID: 26567277
[TBL] [Abstract][Full Text] [Related]
11. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
12. [Role of anidulafungin in solid organ transplant recipients].
Aguado JM; Ayats J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():29-34. PubMed ID: 19572432
[TBL] [Abstract][Full Text] [Related]
13. [Anidulafungin: experimental therapy of fungal infections in animal models].
Pastor FJ; Guarro J
Rev Iberoam Micol; 2008 Jun; 25(2):119-23. PubMed ID: 18473506
[TBL] [Abstract][Full Text] [Related]
14. [Liver dysfunctions in intensive care patients--consequences for the treatment of invasive Candida infections].
Canbay AE; Glöckner A
Med Klin Intensivmed Notfmed; 2015 Apr; 110(2):138-44. PubMed ID: 23797458
[TBL] [Abstract][Full Text] [Related]
15. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
Wilke M
Eur J Med Res; 2011 Apr; 16(4):180-6. PubMed ID: 21486732
[TBL] [Abstract][Full Text] [Related]
16. [Potential of anidulafungin in hematological patients].
Vázquez López L; Ruiz Camps I
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():44-50. PubMed ID: 19572434
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
18. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis.
Cheng SC; Scicluna BP; Arts RJ; Gresnigt MS; Lachmandas E; Giamarellos-Bourboulis EJ; Kox M; Manjeri GR; Wagenaars JA; Cremer OL; Leentjens J; van der Meer AJ; van de Veerdonk FL; Bonten MJ; Schultz MJ; Willems PH; Pickkers P; Joosten LA; van der Poll T; Netea MG
Nat Immunol; 2016 Apr; 17(4):406-13. PubMed ID: 26950237
[TBL] [Abstract][Full Text] [Related]
19. Invasive aspergillosis: adjunctive combination therapy.
Ruhil S; Balhara M; Dhankhar S; Kumar V; Chhillar AK
Mini Rev Med Chem; 2012 Oct; 12(12):1261-72. PubMed ID: 22625414
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial.
Vazquez J; Reboli AC; Pappas PG; Patterson TF; Reinhardt J; Chin-Hong P; Tobin E; Kett DH; Biswas P; Swanson R
BMC Infect Dis; 2014 Feb; 14():97. PubMed ID: 24559321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
